Wellington Management Group LLP boosted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,671,157 shares of the company

Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics

Teva Pharmaceutical Industries (NYSE:TEVA) vuelve a estar en el centro de atención después de que la Administración de Alimentos y Medicamentos de EE. UU. aceptara su solicitud de nuevo fármaco para ecopipam, el primer tratamiento pediátrico del síndrome de Tourette. A pesar de que el precio de las acciones bajó alrededor del 3% durante el último día y del 2% durante la semana pasada, Teva Pharmaceutical Industries tiene un rendimiento del precio de las acciones en 1 mes de aproximadamente el 4% y un rendimiento del precio de las acciones en lo que va del año de alrededor del 18%, mientras que el rendimiento total para los accionistas durante el año pasado es cercano al 100%. Este...

Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire a neuroscience asset from BioXcel Therapeutics involving a sublingual film for agitation in schizophrenia and bipolar disorder patients through a court supervised bankruptcy sale. The product is under FDA review, and the transaction remains subject to court approval as of late August 2026. The deal aligns with Teva's stated Pivot to Growth strategy and adds to its focus on neuroscience treatments. For readers looking to explore...

Teva Pharmaceutical Industries stock has delivered a very strong 284.4% gain over the past 5 years, yet current checks send mixed signals as the Discounted Cash Flow (DCF) estimate points to undervaluation while market based multiples screen the shares as expensive. Investors looking at Teva today see a stock with powerful recent momentum against a low overall value score that suggests it is not a straightforward bargain. A 284.4% return over 5 years highlights how much Teva has already...

Teva Pharmaceuticals bids for BioXcel's dexmedetomidine film, pending FDA review, to treat agitation